Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biotechnology
Vertex, Ribometrix to develop RNA-targeted small molecules
by Lisa M. Jarvis
October 6, 2019
| A version of this story appeared in
Volume 97, Issue 39
Vertex Pharmaceuticals will pay Ribometrix $20 million to develop up to three RNA-targeted small-molecule treatments. The partners are not identifying drug targets, but Ribometrix previously disclosed to C&EN that it is pursuing molecules that bind to messenger RNA related to the cancer driver c-Myc and that target mRNA connected with the protein implicated in Huntington’s disease. Ribometrix was founded in 2017 based on discoveries of chemist Kevin Weeks at the University of North Carolina at Chapel Hill.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter